Education
About Us
Working with TipRanks
Follow Us
Bioline RX Ltd Sponsored ADR (BLRX)
NASDAQ:BLRX
RESEARCH TOOLSreports
BLRX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.88 - $54.00
Previous CloseN/A
Volume8.80M
Average Volume (3M)52.67K
Market Cap
$12.61M
Enterprise Value$43.31M
Total Cash (Recent Filing)$4.25M
Total Debt (Recent Filing)$11.59M
Price to Earnings (P/E)―
Beta1.74
Next Earnings
Mar 26, 2025EPS Estimate
-0.81Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-10.72
Shares Outstanding3,721,003
10 Day Avg. Volume23,705
30 Day Avg. Volume52,673
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2.65
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market Cap3.43
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit39.09
Enterprise Value/Ebitda-3.50
Forecast
1Y Price Target
$5.50Price Target Upside53.63% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering0
---
Bioline RX Ltd Sponsored ADR News
PremiumCompany Announcements
BioLineRx Adjusts ADS Ratio to Maintain Nasdaq Listing
PremiumCompany Announcements
BiolineRx Announces Major Direct Offering to Bolster Operations
---
Bulls Say, Bears Say
Bulls Say
Institutional OrdersInstitutions ordering APHEXDA increased by 40%.
Licensing AgreementBioLineRx will receive a $10M upfront payment, up to $87M in potential commercial milestones, and royalties on net sales from the license agreement with Ayrmid.
Market ShareAPHEXDA continues expanding market share, achieving 10% market share of total CXCR4 inhibitor usage in the U.S.
Bears Say
Debt RepaymentThe company repaid $16.5M of ~$29M in total debt, with the remainder due over the next three years at an annual interest rate of ~11%.
Operating ExpensesExpecting to decrease operating expenses by more than 70% due to the license agreement and headcount changes.
---
Ownership Overview
―
Insiders
1.07% Mutual Funds
0.04% Other Institutional Investors
98.93% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BLRX FAQ
What was Bioline RX Ltd Sponsored ADR’s price range in the past 12 months?
Bioline RX Ltd Sponsored ADR lowest stock price was $2.88 and its highest was $54.00 in the past 12 months.
What is Bioline RX Ltd Sponsored ADR’s market cap?
Bioline RX Ltd Sponsored ADR’s market cap is $12.61M.
When is Bioline RX Ltd Sponsored ADR’s upcoming earnings report date?
Bioline RX Ltd Sponsored ADR’s upcoming earnings report date is Mar 26, 2025 which is in 2 days.
How were Bioline RX Ltd Sponsored ADR’s earnings last quarter?
Bioline RX Ltd Sponsored ADR released its earnings results on Nov 25, 2024. The company reported $0 earnings per share for the quarter, beating the consensus estimate of -$1.742 by $1.742.
Is Bioline RX Ltd Sponsored ADR overvalued?
According to Wall Street analysts Bioline RX Ltd Sponsored ADR’s price is currently Undervalued.
Does Bioline RX Ltd Sponsored ADR pay dividends?
Bioline RX Ltd Sponsored ADR does not currently pay dividends.
What is Bioline RX Ltd Sponsored ADR’s EPS estimate?
Bioline RX Ltd Sponsored ADR’s EPS estimate is -0.81.
How many shares outstanding does Bioline RX Ltd Sponsored ADR have?
Bioline RX Ltd Sponsored ADR has 3,721,003 shares outstanding.
What happened to Bioline RX Ltd Sponsored ADR’s price movement after its last earnings report?
Bioline RX Ltd Sponsored ADR reported an EPS of $0 in its last earnings report, beating expectations of -$1.742. Following the earnings report the stock price went down -2.248%.
Which hedge fund is a major shareholder of Bioline RX Ltd Sponsored ADR?
Currently, no hedge funds are holding shares in BLRX
---
Company Description
Bioline RX Ltd Sponsored ADR
BioLineRx Ltd. is a clinical-stage biopharmaceutical company, which includes indentifying, in-licensing, and developing therapeutic candidates. Its in-licenses novel compounds, primarily from academic institutions and biotech companies based in Israel, and develops them through pre-clinical and clinical stages, and then partners with pharmaceutical companies clinical development and commercialization. The company was founded in April 2003 and is headquartered in Modi'in, Israel.
---
BLRX Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted a major licensing agreement and debt restructuring, which position BioLineRx favorably for future growth and stability. However, challenges remain, including a net loss, closure of U.S. operations, and uncertainty around China market revenues.Read More>---
BLRX Stock 12 Month Forecast
Average Price Target
$5.50
▲(53.63% Upside)
Technical Analysis
Best Analysts Covering BLRX
1 Year
1 Year Success Rate
0/9 ratings generated profit
1 Year Average Return
-83.40%
reiterated a buy rating 4 months ago
Copying Joseph Pantginis's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -83.40% per trade.
---